Form 4: Arcus Biosciences Director Yasunori Kaneko Receives Significant Equity Grant

Arcus Biosciences, Inc. Director Yasunori Kaneko was granted 13,300 restricted stock units and options to purchase 38,300 shares of common stock, aligning his interests with shareholders.

Summary

• Yasunori Kaneko, a Director of Arcus Biosciences, Inc. (RCUS), was granted 13,300 shares of common stock in the form of Restricted Stock Units (RSUs) on June 10, 2025.
• These RSUs vest in full on the earlier of June 10, 2026, or the next annual meeting of stockholders, and will fully vest upon a change in control of the company.
• Additionally, Mr. Kaneko was granted options to purchase 38,300 shares of common stock with an exercise price of $10.02 per share, also on June 10, 2025.
• These stock options will vest in full on the earlier of June 10, 2026, or the next annual meeting of stockholders, and become fully vested and exercisable upon a change in control. The options expire on June 9, 2035.
• Following these transactions, Mr. Kaneko directly beneficially owns 33,300 shares of common stock and 38,300 stock options.
• Indirect beneficial ownership includes 505,050 shares through Kaneko Capital, LLC, 252,524 shares through Kaneko Investments, LLC, and 161,381 shares through a Trust.

Sentiment

Score: 7

Explanation: The grant of equity awards to a director is generally a positive signal as it aligns the director's interests with the company's long-term performance and shareholder value. It's a routine compensation event, not indicative of major news, but inherently positive for governance and incentive alignment.

Positives

• The grant of restricted stock units and stock options to a director aligns management's interests with those of shareholders, incentivizing long-term performance and value creation.
• The vesting schedule, including accelerated vesting upon a change in control, provides a clear incentive for strategic transactions that could benefit shareholders.

Risks

• The value of the granted equity awards is subject to the future performance of Arcus Biosciences' stock price.
• The vesting of the awards is contingent on continued service or a change in control, meaning the awards could be forfeited if conditions are not met.

Future Outlook

This document does not provide a future outlook for the company's financial performance or strategic direction, focusing solely on an insider's equity transaction.

Industry Context

This Form 4 filing details a routine equity grant to a director, which is a common practice in the biotechnology and pharmaceutical industry to incentivize leadership and align their interests with company performance and shareholder value. It does not provide broader industry trends or competitive analysis.

Corporate Governance

Related Party Transactions

• The grant of 13,300 restricted stock units and options for 38,300 shares to Director Yasunori Kaneko constitutes a related party transaction, as it involves compensation from the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: The equity grant aligns the director's financial interests with shareholder value creation, potentially leading to more focused efforts on company performance.
• Employees: While not directly impacting all employees, such grants are part of a broader compensation philosophy that can influence overall company culture and incentive structures.

Next Steps

• Vesting of restricted stock units and stock options on or after June 10, 2026, or the next annual meeting.
• Potential exercise of stock options by June 9, 2035.

Key Dates

Recommendation

Keywords

Arcus Biosciences, RCUS, Form 4, Insider Transaction, Restricted Stock Units, RSU, Stock Options, Equity Grant, Director Compensation, Beneficial Ownership, SEC Filing